Skip to main content
    S

    Stereotaxis Inc (STXS)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • AMEX

    $0.81
    -0.04 (-4.48%)

    Market Cap: $85.02M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Stereotaxis Inc (STXS) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Stereotaxis (STXS) trades at 2.6x sales and 3.9x book value. Its P/S of 2.6x is below its 5-year median of 6.1x. Its forward P/E is 19.6x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E19.6x
    Price to sales2.6x
    Price to book3.9x
    PEGN/A
    FCF yield-18.8%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 53.6% below 5.6x and its P/B is 64.9% below 11.1x.

    MultipleCurrent5-year median10-year median
    P/S2.6x6.1x5.6x
    P/B3.9x11.1x11.1x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 98 to 114 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 0.4x in 2016 to 110.5x in 2019.

    Year endPriceP/SP/B
    2025$2.306.5x11.8x
    2024$2.287.2x17.3x
    2023$1.755.3x6.6x
    2022$2.075.6x4.9x
    2021$6.2013.4x11.9x
    2020$5.0913.9x9.5x
    2019$5.29110.5x12.6x
    2018$1.081.8x8.8x
    2017$0.800.6xN/A
    2016$0.650.4xN/A
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About STXS

    What is STXS's forward P/E ratio?

    Stereotaxis has a forward P/E ratio of 19.6x.

    Is STXS stock overvalued?

    GNG's valuation label for STXS is Undervalued.

    What is STXS's price to sales ratio?

    Stereotaxis has a price to sales ratio of 2.6x.